Savara is a pre-revenue biotechnology company in a golden cross breakout with 78% analyst price target upside, but quality scores only 1.6 out of 10 with fully negative free cash flow and a put/call ratio of 28.33 — the highest in this group — signaling extreme options market bearishness despite the bullish technical setup.
Thesis pillars
- Extreme Put Call Bearish Signal↓Deteriorating
- Bullish Breakout Technical Setup↑Improving
- Quality Below Floor Cash Burn→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 13, 2026
Savara, Inc. (SVRA) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $5.02: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Below long-term trend.
Savara is a clinical-stage biopharmaceutical company developing MOLBREEVI, an inhaled GM-CSF biologic and its sole product candidate, for autoimmune pulmonary alveolar proteinosis, a rare lung disease with no FDA-approved treatments. The company has no approved products or... Read more
Sell if holding. Engine safety override at $5.02: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 54. Score 5.1/10, moderate confidence.
Passes 7/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Savara, Inc.
Latest news
- NEWS Savara Presents New Clinical Data for Molgramostim in aPAP Patients — fiscal.ai Oct 21, 2026 neutral
- NEWS Savara Presents Clinical Trial Post-Hoc Analysis Of IMPALA At CHEST 2026 Annual Meeting To Evaluate Effects Of Molgramos — benzinga Oct 21, 2026 positive
- NEWS JP Morgan Initiates Coverage On Savara with Overweight Rating, Announces Price Target of $12 — benzinga Oct 7, 2026 positive
- NEWS BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday — benzinga Oct 7, 2026 neutral
- NEWS Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS — benzinga Aug 24, 2026 positive
Generated 2026-10-29T12:03:45Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.02: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 54. Prior stop was $4.67. Score 5.1/10, moderate confidence.
Analyst target: $9.62 (+91.6% upside). Prior stop was $4.67. Stop-loss: $4.67.
Quality below floor (1.6 < 4.0); Value-trap signals (2/5): Margin compression (op margin -11.4%), Material insider selling (14 sells, 0.15% of cap).
Savara, Inc. trades at a P/E of N/A (forward -13.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
14 analysts cover SVRA with a consensus score of 4.3/5. Average price target: $11.
What does Savara, Inc. do?Savara is a clinical-stage biopharmaceutical company developing MOLBREEVI, an inhaled GM-CSF biologic and its sole...
Savara is a clinical-stage biopharmaceutical company developing MOLBREEVI, an inhaled GM-CSF biologic and its sole product candidate, for autoimmune pulmonary alveolar proteinosis, a rare lung disease with no FDA-approved treatments. The company has no approved products or commercial revenue; the FDA formally filed Savara's resubmitted Biologics License Application for MOLBREEVI in February 2026 and granted Priority Review. Savara outsources manufacturing to third-party partners including Fujifilm for drug substance and PARI for its proprietary nebulizer delivery device.